|
US4880935A
(en)
|
1986-07-11 |
1989-11-14 |
Icrf (Patents) Limited |
Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
|
|
US5128318A
(en)
|
1987-05-20 |
1992-07-07 |
The Rogosin Institute |
Reconstituted HDL particles and uses thereof
|
|
GB8712540D0
(en)
|
1987-05-28 |
1987-07-01 |
Ucb Sa |
Expression of human proapolipoprotein a-i
|
|
IL106992A
(en)
|
1988-02-11 |
1994-06-24 |
Bristol Myers Squibb Co |
Acylhydrazone derivatives of anthracycline and methods for their preparation
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US5220043A
(en)
|
1991-03-21 |
1993-06-15 |
Ohio University |
Synthesis of D-erythro-sphingomyelins
|
|
SE9103701D0
(sv)
|
1991-12-13 |
1991-12-13 |
Kabi Pharmacia Ab |
Apolipoprotein
|
|
US5622929A
(en)
|
1992-01-23 |
1997-04-22 |
Bristol-Myers Squibb Company |
Thioether conjugates
|
|
CA2185450A1
(en)
|
1994-03-22 |
1995-09-28 |
Patrick Tso |
Eating suppressant peptides
|
|
DK0871490T3
(da)
|
1995-12-22 |
2003-07-07 |
Bristol Myers Squibb Co |
Forgrenede hydrazonlinkere
|
|
US6046166A
(en)
|
1997-09-29 |
2000-04-04 |
Jean-Louis Dasseux |
Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
|
|
US6004925A
(en)
|
1997-09-29 |
1999-12-21 |
J. L. Dasseux |
Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
|
|
US6037323A
(en)
|
1997-09-29 |
2000-03-14 |
Jean-Louis Dasseux |
Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
|
|
DE60117781T2
(de)
|
2000-04-21 |
2006-11-23 |
Amgen Inc., Thousand Oaks |
Peptidderivate des apolipoproteins-a1/aii
|
|
US7148197B2
(en)
|
2000-08-24 |
2006-12-12 |
The Regents Of The University Of California |
Orally administered small peptides synergize statin activity
|
|
US7144862B2
(en)
|
2000-08-24 |
2006-12-05 |
The Regents Of The University Of California |
Orally administered peptides to ameliorate atherosclerosis
|
|
US6664230B1
(en)
|
2000-08-24 |
2003-12-16 |
The Regents Of The University Of California |
Orally administered peptides to ameliorate atherosclerosis
|
|
US7199102B2
(en)
|
2000-08-24 |
2007-04-03 |
The Regents Of The University Of California |
Orally administered peptides synergize statin activity
|
|
BR0115257A
(pt)
|
2000-11-10 |
2003-08-12 |
Proteopharma Aps |
Análogos de apolipoproteìna
|
|
US7217785B2
(en)
|
2001-05-09 |
2007-05-15 |
The Regents Of The University Of California |
Cysteine-containing peptides having antioxidant properties
|
|
DE60226881D1
(de)
|
2001-08-20 |
2008-07-10 |
Zlb Bioplasma Ag |
High-density -lipoprotein zur behandlung von schlaganfällen und ischämiezuständen
|
|
US7223726B2
(en)
|
2002-01-14 |
2007-05-29 |
The Regents Of The University Of California |
Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
|
|
JP2006507223A
(ja)
|
2002-05-17 |
2006-03-02 |
エスペリオン セラピューティクス，インコーポレイテッド |
脂質代謝異常疾患の治療方法
|
|
EP1545576A2
(en)
|
2002-07-30 |
2005-06-29 |
Esperion Therapeutics Inc. |
Methods of using non-human animal apoliprotein a-i protein
|
|
TWI433693B
(zh)
|
2003-02-14 |
2014-04-11 |
Childrens Hosp & Res Ct Oak |
親脂藥物傳送媒介物及其使用方法
|
|
KR101185609B1
(ko)
|
2004-07-16 |
2012-09-24 |
트러스티즈 오브 터프츠 칼리지 |
아포리포단백질 ａ１ 미메틱 및 이의 용도
|
|
US8206750B2
(en)
|
2005-03-24 |
2012-06-26 |
Cerenis Therapeutics Holding S.A. |
Charged lipoprotein complexes and their uses
|
|
EP1917278A2
(en)
|
2005-08-26 |
2008-05-07 |
Cerenis Therapeutics Holding SA |
Compositions and methods for producing apolipoprotein gene products in lactic acid bacteria
|
|
US20070254832A1
(en)
*
|
2006-02-17 |
2007-11-01 |
Pressler Milton L |
Methods for the treatment of macular degeneration and related eye conditions
|
|
US8541236B2
(en)
|
2006-12-08 |
2013-09-24 |
University Of Washington |
Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls
|
|
US20080293102A1
(en)
|
2007-02-28 |
2008-11-27 |
Cerenis Therapeutics Holding, S.A. |
Compositions and methods for producing apolipoprotein
|
|
US9173890B2
(en)
|
2007-09-20 |
2015-11-03 |
Abbott Cardiovascular Systems Inc. |
Sustained release of Apo A-I mimetic peptides and methods of treatment
|
|
WO2009055538A1
(en)
|
2007-10-23 |
2009-04-30 |
The Cleveland Clinic Foundation |
Oxidant resistant apolipoprotein a-1 and mimetic peptides
|
|
JP5719783B2
(ja)
|
2009-02-16 |
2015-05-20 |
セレニス セラピューティクス ホールディング エスアー |
アポリポタンパクａ−ｉ模倣物
|
|
US20130137628A1
(en)
|
2010-05-11 |
2013-05-30 |
Esperion Therapeutics, Inc. |
Dimeric Oxidation-Resistant Apolipoprotein A1 Variants
|
|
HUE042314T2
(hu)
|
2011-02-07 |
2019-06-28 |
Cerenis Therapeutics Holding Sa |
Lipoprotein komplexek és azok gyártása és alkalmazásai
|
|
CN113679699B
(zh)
*
|
2012-09-12 |
2022-10-28 |
诺瓦利克有限责任公司 |
包含半氟化烷烃的混合物的组合物
|
|
EP3842443B1
(en)
|
2013-03-15 |
2025-02-19 |
Cerenis Therapeutics Holding SA |
Methods for the synthesis of sphingomyelins and dihydrosphingomyelins
|
|
US9708354B2
(en)
|
2013-03-15 |
2017-07-18 |
Cerenis Therapeutics Holding Sa |
Methods for the synthesis of sphingomyelins and dihydrosphingomyelins
|
|
CA2947127A1
(en)
|
2014-05-02 |
2015-11-19 |
Cerenis Therapeutics Holding Sa |
Hdl therapy markers
|
|
JP6818264B2
(ja)
|
2014-12-25 |
2021-01-20 |
国立大学法人京都大学 |
高密度リポタンパク質およびその細胞親和性ペプチドを融合した高密度リポタンパク質の点眼による後眼部薬物デリバリー
|
|
AU2018226872A1
(en)
*
|
2017-03-03 |
2019-09-05 |
Macregen, Inc. |
Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents
|
|
JP2020528082A
(ja)
*
|
2017-07-17 |
2020-09-17 |
ロイズマン，キース |
加齢黄斑変性と他の眼疾患の治療用の細胞透過性ペプチドを使用する治療薬の局所送達
|
|
ES2984286T3
(es)
|
2017-08-10 |
2024-10-29 |
Abionyx Pharma Sa |
Apómeros
|
|
EP3668600B1
(en)
|
2017-08-10 |
2024-05-15 |
Abionyx Pharma SA |
Cargomers
|
|
CN111902144A
(zh)
*
|
2018-03-30 |
2020-11-06 |
第一三共株式会社 |
Lcat缺乏的治疗剂
|